Publikace
- Olaparib Synergizes the Anticancer Activity of Daunorubicin via Interaction with AKR1C32020 | Farmaceutická fakulta v Hradci Králové
- Cyclin-dependent kinase inhibitors AZD5438 and R547 show potential for enhancing efficacy of daunorubicin-based anticancer therapy: Interaction with carbonyl-reducing enzymes and ABC transporters2019 | Farmaceutická fakulta v Hradci Králové
- Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C32019 | Farmaceutická fakulta v Hradci Králové
- Anthracycline resistance mediated by reductive metabolism in cancer cells: The role of aldo-keto reductase 1C32014 | Farmaceutická fakulta v Hradci Králové
- In Vitro Transfection Mediated by Dendrigraft Poly(L-lysines): The Effect of Structure and Molecule Size2013 | Publikace bez příslušnosti k fakultě
- Tazemetostat synergistically combats multidrug resistance by the unique triple inhibition of ABCB1, ABCC1, and ABCG2 efflux transporters in vitro and ex vivo2023 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Sonidegib potentiates the cancer cells' sensitivity to cytostatic agents by functional inhibition of ABCB1 and ABCG2 in vitro and ex vivo2022 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Talazoparib Does Not Interact with ABCB1 Transporter or Cytochrome P450s, but Modulates Multidrug Resistance Mediated by ABCC1 and ABCG2: An in Vitro and Ex Vivo Study2022 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Encorafenib Acts as a Dual-Activity Chemosensitizer through Its Inhibitory Effect on ABCC1 Transporter In Vitro and Ex Vivo2022 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy2022 | Farmaceutická fakulta v Hradci Králové
Loading network view...